# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-27T00:38:27.251632
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 18903 in / 4469 out
**Response SHA256:** 4fedb092eb205112

---

## Summary

The paper’s central point—that naive cross-border designs using Facebook’s Social Connectedness Index (SCI) can be badly confounded by “cosmopolitan” local characteristics—is important and plausibly novel as a *design-diagnostic contribution*. The empirical “Brexit → French housing” application is useful primarily as a laboratory for the diagnostic toolkit rather than as a clean causal estimate of a Brexit effect.

However, as currently written, the paper is **not yet publication-ready for a top general-interest journal** because (i) the *main causal object* is not stably identified across designs (baseline DiD vs triple-diff vs GADM1 battery vs epoch split), (ii) the triple-difference identifying assumption is not adequately defended against *type-specific within-department shocks* correlated with UK exposure (especially post-2020), and (iii) inference/power issues arise when treatment variation is effectively at the **GADM1 (13-region)** level while SEs are clustered at **96 departments**. The paper has many strong robustness instincts (placebos, bootstrap, permutation), but the causal interpretation remains fragile.

What follows is a review focused on identification, inference, and scientific readiness, not prose or exhibit aesthetics.

---

## 1. Identification and empirical design (critical)

### A. Baseline DiD (eqs. (1) and (2); Table 1; Figure 3)
**Claimed estimand:** causal effect of Brexit shock interacted with continuous “exposure” (SCI or census stock).

**Core problem (acknowledged by authors):** exposure is correlated with amenities/urbanization/international openness, generating differential trends (“cosmopolitan confounding”). The German placebo being larger than UK in the baseline DiD (Table 1 col. 5 vs col. 1) is compelling evidence that eq. (2) is not credible for causal interpretation.

**Additional identification concerns beyond “cosmopolitan confounding”:**
- **Post-treatment measurement of SCI (2021):** Using 2021 SCI to study a 2016 shock risks endogenous exposure measurement (migration/friendship changes post-2016). You acknowledge this and motivate census stock as predetermined, but you still lean on SCI in key diagnostics (epoch decomposition, triple-diff point estimates, placebos). This needs sharper separation: *SCI-based results are design diagnostics, not causal evidence*, unless you can bound/argue stability of SCI rankings.
- **Parallel trends already look questionable:** Event-study pretrend tests are borderline significant for both SCI and census stock (Figure 3; joint pretests p≈0.04–0.05). For a top journal, “borderline” is not reassuring, especially because continuous-treatment pretrend tests can be underpowered/misleading depending on normalization and heterogeneous trends.

**Bottom line:** baseline DiD is useful as a *negative result / diagnostic*, but not as an identification strategy for the paper’s substantive economic claim.

### B. Triple-difference houses vs apartments (eq. (3); Table 2; Figures 4 and 11)
This is the paper’s main proposed fix: department×quarter fixed effects absorb all time-varying department shocks, leaving identification from within-department differential evolution of house vs apartment prices by exposure.

**What this buys you:** it directly targets the cosmopolitan trend issue showcased by Germany: Germany becomes null in triple-diff (Table 2 col. 4). That is a real strength.

**But the triple-diff assumption is still strong and currently under-defended:**
- Your identifying assumption is essentially:  
  *Absent UK-specific demand, exposure is unrelated to shocks to the house–apartment relative price within a department.*
- The most serious threat is exactly what your timing results suggest: **post-2020 rural/space/WFH shocks are property-type-specific** and plausibly stronger in the kinds of departments that also have high UK connectedness (rural, amenity-rich). You add two controls (inverse density proxy; Channel proximity) (Table 8), but they are blunt and may not capture the relevant *type-specific* boom heterogeneity (e.g., second homes, renovation potential, land availability, preexisting housing stock composition, differential supply elasticity, telework adoption, local income composition).
- The epoch decomposition (Table 6) is a double-edged sword. It is commendably honest, but it undermines the *Brexit laboratory* narrative: the triple-diff “signal” for SCI is **zero in 2016–2019** and appears **only after 2020**. That pattern is at least as consistent with “COVID-era house boom heterogeneity correlated with UK exposure” as it is with delayed Brexit effects.
- The triple-diff results are **not stable across exposure measures**: SCI yields ~0.029 (p=0.106; bootstrap p=0.054), while census stock yields ~0.003 (p=0.57). If census stock is your “clean” exposure, the triple-diff does not corroborate it.

**Key design gap:** You do not show direct evidence that British demand differentially loads on *houses vs apartments* in a way that is (i) large enough and (ii) plausibly stable over time, and (iii) differential across departments in proportion to your exposure measure. Without buyer nationality, this must be triangulated more convincingly (see revision requests).

### C. Multi-country placebo battery and resolution harmonization (Table 4; Sections 3.4 and 5.4)
The harmonization point is important and underappreciated in the broader SCI literature: mixed geographic resolution can generate mechanical differences in variance and confounding.

However, the harmonized battery creates **new identification/inference questions**:
- At GADM1 you have **only 13 regions** worth of exposure variation. Yet you cluster at the department level (96 clusters), which can overstate precision when the regressor varies at a coarser level (classic “Moulton” concerns / effective clusters). You flag this in limitations, but in a top journal this must be dealt with formally.
- In the **GADM1 triple-diff**, multiple placebos (Belgium/Italy/Spain) become significant individually (Table 4). This weakens the claim that the triple-diff “solves” cosmopolitan confounding in general. It may instead be picking up real cross-border demand channels (your discussion) *or* spatially structured type-specific shocks correlated with European connectedness more broadly.

**Overall:** the placebo batteries are a major strength, but the paper needs a clearer statement of what pattern of placebo results would *validate* the design versus *falsify* it, and then a candid conclusion about whether that validation is achieved for the preferred estimand.

---

## 2. Inference and statistical validity (critical)

### A. Standard errors, clustering, small-cluster issues
- You generally report clustered SEs and sometimes p-values. Good.
- With 96 departments, cluster-robust asymptotics are often acceptable, and you add pairs cluster bootstrap (Table 9), which is helpful.

**But key remaining inference issues:**
1. **Regressor variation at higher aggregation than clustering (GADM1):** When exposure is measured at region level (13), department-clustered SEs can be misleading because residual correlation is likely within region and the regressor is constant within region. At minimum you should:
   - cluster at the **treatment-variation level** (region) or use **two-way clustering** (department and region) if applicable, and/or
   - use **randomization inference at the region level**, and/or
   - use **wild cluster bootstrap** with clusters = 13 regions (recognizing low power but honest size control).
   Right now, the “UK only significant at GADM1 DiD” result (Table 4 left panel) could be overstated.

2. **Multiple hypothesis testing / specification search risk in placebo batteries:** You partially address with Bonferroni in Table 4 notes, but you do not apply systematic family-wise error control across the *full set* of placebo exercises and epochs/specifications. Given the paper’s diagnostic theme, you should pre-specify a testing family and adjust accordingly (or report sharpened q-values).

3. **Event-study inference:** You report joint F-tests for pretrends. For credibility, you should also show (or at least report) the *number of leads*, the exact lead/lag window, and whether you use Sun–Abraham / Callaway–Sant’Anna style methods (not applicable here since treatment is common timing but continuous exposure) or conventional two-way FE event study (likely OK). Still, the lead coefficients in Figure 3 matter; the borderline pretrend tests are concerning.

4. **Power and precision in triple-diff:** You argue imprecision is expected. Fine, but then the paper should not lean on marginal significance (bootstrap p=0.054) as evidence of a UK-specific causal effect. In a top journal, the triple-diff should either (i) be convincingly powered via a more granular design with appropriate clustering/inference (commune-level helps but still clustered at 96), or (ii) be presented clearly as suggestive, not confirmatory.

### B. Sample sizes and coherence
- Panel sizes are mostly coherent, and you explain singleton drops. Good.
- One red flag: the paper sometimes interprets results across designs with different effective identifying variation (department vs region; department-quarter missingness tied to transaction counts). You should show that missing department-quarter cells are not correlated with exposure *differentially by property type* post-2016/post-2020 (a selection threat).

---

## 3. Robustness and alternative explanations

### Strengths
- Placebo with Germany is well-motivated and informative (Table 1 vs Table 2).
- Harmonized placebo battery is conceptually excellent (Section 3.4; Table 4).
- You run permutation inference and leave-one-out (Figures 9–10).
- You attempt COVID disentanglement (Table 8).
- HonestDiD sensitivity is a plus (Figure 8), though it is applied to the baseline census-stock DiD which you yourself view as confounded by pretrends/cosmopolitan trends.

### Key gaps / needed robustness
1. **Direct validation of the “houses vs apartments” channel.** This is the lynchpin. Without nationality of buyers, you need stronger triangulation:
   - Use external administrative/notarial microdata if available (even in a subset/region) to show British buyers overwhelmingly buy houses and that this propensity changed around Brexit/COVID.
   - Alternatively, use *within-DVF* proxies: second-home indicators (if any), property characteristics (surface, land, rural vs urban commune classification), or buyer type if recorded (individual vs entity), to demonstrate the composition difference plausibly linked to UK demand.

2. **Alternative within-department type-specific shocks.** You need to show that your triple-diff result is not explained by:
   - differential supply elasticity for houses vs apartments correlated with UK exposure,
   - differential renovation/energy efficiency policy impacts by housing type and rurality (France has multiple housing/energy policy changes in 2019–2023),
   - differential tourism/second-home demand by type,
   - migration from Paris to high-amenity rural areas (which could be correlated with UK exposure even after density controls).

3. **More structured COVID-era controls / interacted trends.** The current “rural amenity proxy” is transaction density, which is endogenous to the housing market and may not proxy WFH desirability well. Consider:
   - pre-period (2014–2015) density/population from INSEE, land-use share, broadband availability, commute times, share of teleworkable occupations, etc., interacted with House×Post2020.

4. **Heterogeneity results (Table 11) are not informative as written.** Both “channel vs interior” and “hotspot vs non-hotspot” show positive effects in both groups, often similar magnitudes, which does not corroborate a UK-specific demand story. You should test *differences* (e.g., triple interaction with exposure×post×group and report the differential) rather than separate coefficients that are hard to interpret.

---

## 4. Contribution and literature positioning

### Contribution
- The “cosmopolitan confounding” framing is a useful label for a real empirical pitfall: SCI capturing openness/amenities rather than bilateral exposure.
- The paper’s best contribution is methodological: **diagnostic tests and design principles for SCI-based cross-border exposure research**, especially the emphasis on (i) multi-country placebos and (ii) resolution harmonization.

### Literature to add / engage more precisely
You cite Bailey et al. and shift-share design papers, which is good. For a top journal, consider explicitly connecting to:
- **Moulton (1990)** on grouped regressors and understated SEs when regressor varies at higher aggregation—relevant for GADM1 results and clustering.
- **Abadie et al. (2023/2024)** work on permutation/randomization inference and placebo tests in panel settings (depending on what you use).
- **de Chaisemartin & D’Haultfoeuille (2020+)** not for staggered timing (not your case) but for modern DiD diagnostics and placebo logic; at minimum, position why continuous exposure DiD still faces parallel-trends issues.
- Housing demand shocks and foreign buyers: beyond Badarinza–Ramadorai–Ramos (2019), include work on *second homes/tourism demand* and COVID-era housing shifts in Europe/France if you want to interpret post-2020 effects.

---

## 5. Results interpretation and claim calibration

The paper is relatively careful in Sections 6–9 in stating that it does **not** identify a clean “Brexit referendum effect.” That is good.

Still, there are internal tensions that need tightening:
- You sometimes describe the census-stock DiD as “most robust” (e.g., Table 1 discussion) even though:
  - pretrends are borderline in the event study (Figure 3),
  - department-specific trends kill the effect (Table 1 col. 6; Table 10 col. 6),
  - the triple-diff using census stock is near zero (Table 2 col. 2).
  Those facts don’t mean the effect is false, but they mean “robust” is too strong without a clearer statement of *what variation identifies the effect* and why it is plausibly causal.

- The triple-diff SCI result is portrayed as “positive UK-specific coefficient” with p≈0.10 and bootstrap p≈0.054. For a top journal, this should be framed as **suggestive** unless you can (i) strengthen identification against type-specific shocks, and (ii) resolve inconsistency with census stock.

- The GADM1 battery: you emphasize “UK is the only significant country in the baseline DiD” (Table 4), but then in triple-diff several placebos become significant. This mixed message should be reconciled: is the diagnostic toolkit “progressively resolving” confounding, or does it show that *different confounds dominate at different resolutions*?

---

## 6. Actionable revision requests (prioritized)

### 1) Must-fix issues before acceptance

1. **Fix inference when exposure varies at GADM1 (13 regions).**  
   - **Why it matters:** Department-clustered SEs can severely understate uncertainty with grouped regressors; this can flip “UK-only significant” conclusions in Table 4.  
   - **Concrete fix:** Re-estimate GADM1 DiD/triple-diff with (i) clustering at region, (ii) wild cluster bootstrap with 13 clusters, and/or (iii) randomization inference at the region level. Report how significance changes. If precision collapses, interpret accordingly.

2. **Provide a stronger defense (or redesign) of the triple-diff identifying assumption against type-specific within-department shocks post-2020.**  
   - **Why it matters:** Your own epoch decomposition suggests the estimated “effect” aligns with the COVID-era house boom, the exact scenario where house vs apartment shocks differ systematically by rurality/amenities.  
   - **Concrete fix:** Add interacted controls measured pre-2016 (INSEE): density, teleworkability, income, age structure, second-home share, land-use, housing stock composition, broadband. Interact them with House×Post2020 (or House×time) inside the triple-diff. Show whether δ_UK survives.

3. **Reconcile SCI vs census-stock exposure inconsistency in triple-diff.**  
   - **Why it matters:** If the “clean” predetermined exposure (census stock) does not show the effect in the preferred design, the causal channel is not established.  
   - **Concrete fix:** (i) Show first-stage relationship between census stock and SCI across departments/communes; (ii) instrument SCI with census stock (or vice versa) as a robustness exercise (acknowledging exclusion limits) to see whether the SCI triple-diff is driven by components unrelated to stock; (iii) explore measurement error in stock (zeros, aggregation) and use alternative functional forms (levels, asinh, bins).

4. **Address selection from missing department-quarter cells and minimum-transaction thresholds by property type.**  
   - **Why it matters:** If thin markets drop out differentially post-2020 in high-exposure rural areas, the house–apartment gap could be mechanically distorted.  
   - **Concrete fix:** Show missingness rates by exposure (pre/post; by type), and re-run key results using (i) alternative thresholds, (ii) weighted regressions by transaction count, and/or (iii) imputation/robustness to keeping sparse cells.

### 2) High-value improvements

5. **Strengthen validation that British demand concentrates in houses (not apartments), and that this is the relevant margin.**  
   - **Why it matters:** Triple-diff logic hinges on differential exposure by type.  
   - **Concrete fix:** Bring in any auxiliary evidence: notarial nationality data (even limited), surveys, or administrative migration/housing purchase stats; or DVF-based proxies (rural commune classification; property size/land; second-home indicators if available). At minimum, show that the *share of house transactions* (or house price dynamics) in high-UK-stock areas behaves differently than apartment dynamics in ways consistent with a UK-demand channel.

6. **Clarify the paper’s main estimand and reorganize around the diagnostic contribution.**  
   - **Why it matters:** Right now, readers can come away thinking the paper is estimating a Brexit effect, but the evidence points to a post-2020 phenomenon.  
   - **Concrete fix:** Promote the methodological contribution to the primary narrative; demote “Brexit effect size” to an illustration. State explicitly: baseline DiD is intentionally flawed; triple-diff is the preferred diagnostic; the substantive takeaway is about design hazards and partial remedies.

7. **Multiple-testing discipline across placebos/epochs/specifications.**  
   - **Why it matters:** With many placebos and splits, some significant findings are expected by chance.  
   - **Concrete fix:** Define families (e.g., placebo countries within a table; epoch splits) and report adjusted p-values or q-values; alternatively, pre-specify a primary placebo (Germany) and treat others as exploratory.

### 3) Optional polish (nontrivial but not essential)

8. **More explicit connection to grouped-regressor inference (Moulton) and to general “exposure designs” beyond shift-share.**  
9. **Explore an alternative within-unit design not relying on houses vs apartments** (e.g., rural vs urban communes within department; or distance-to-amenities bins) to show the diagnostic generalizes beyond one particular type split.

---

## 7. Overall assessment

### Key strengths
- Important and credible *diagnosis* that SCI-based cross-border exposure designs can be confounded by cosmopolitan/amenity trends; Germany placebo in baseline DiD is persuasive.
- Strong “research hygiene”: multiple placebos, resolution harmonization attempt, bootstrap, permutation, leave-one-out, and candid timing discussion.
- The triple-difference with department×quarter FE is a thoughtful attempt to absorb confounding that plagues standard designs.

### Critical weaknesses
- The preferred causal signal is not stable across exposure measures and timing (SCI vs census stock; pre-2020 vs post-2020).
- Triple-diff identifying assumption remains vulnerable to post-2020 type-specific shocks correlated with UK exposure; current controls are insufficient.
- Inference is potentially invalid for the harmonized (GADM1) exercises because effective variation is at 13 regions, not 96 departments.

### Publishability after revision
The paper is promising as a top-field-methods/AEJ:Policy style contribution *if* it (i) corrects grouped-regressor inference, (ii) more convincingly defends or augments the triple-diff design against post-2020 heterogeneity, and (iii) reframes the substantive claim tightly around diagnostics rather than “Brexit caused X.” Without those fixes, the main results read as an instructive cautionary tale but not as a publication-ready scientific design toolkit with validated performance.

DECISION: MAJOR REVISION